↓ Skip to main content

Cochrane Database of Systematic Reviews

Rituximab for relapsing-remitting multiple sclerosis

Overview of attention for article published in this source, December 2011
Altmetric Badge

Mentioned by

1 policy source
3 tweeters


9 Dimensions

Readers on

22 Mendeley
Rituximab for relapsing-remitting multiple sclerosis
Published by
John Wiley & Sons, Ltd, December 2011
DOI 10.1002/14651858.cd009130.pub2
Pubmed ID

He, Dian, Zhou, Hongyu, Han, Wenjie, Zhang, Shihong


More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately ten years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RR-MS) convert to secondary progressive MS. Quality of life is considerably impaired in early RR-MS. The increased costs are associated with relapse occurrence and increasing disease severity. Pharmaceutical interventions aimed at delaying the progression of disease may help to reduce the economic burden of MS. It has been showed that B lymphocytes involve in the pathophysiology of MS and rituximab lyses B cells via complement and antibody-dependent cellular cytotoxicity. Current clinical trials are evaluating the role of rituximab as a B-cell-targeted therapy in the treatment of RR-MS.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 9%
Spain 1 5%
Singapore 1 5%
Switzerland 1 5%
Unknown 17 77%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 27%
Professor > Associate Professor 2 9%
Student > Postgraduate 2 9%
Professor 2 9%
Student > Ph. D. Student 2 9%
Other 4 18%
Unknown 4 18%
Readers by discipline Count As %
Medicine and Dentistry 10 45%
Agricultural and Biological Sciences 3 14%
Neuroscience 2 9%
Business, Management and Accounting 1 5%
Unknown 6 27%